Allergan Sales, LLC

FDA recalling firm · 8 enforcement events · 14 product records · 2015–2024 · TX, CA

Allergan Sales, LLC has 8 FDA enforcement events on this register (14 product records) between 2015 and 2024: 7 drug and 1 device; the busiest year was 2017 with 3.

0% of its events are Class I; the most common class is Class II (6). 1 event is listed as ongoing; the recalling firm's address is in TX and CA.

Recall classification reflects the relative degree of health hazard. Event counts depend on a firm's size and product range; they are not a comparison of one firm with another.

Enforcement events

Initiated	Product (first record)	Type	Class	Records	Status
14 Mar 2024	Keller Funnel 2, REF: HA-001, STERILEEO, Rx Only,	Device	Class II	1	Ongoing
19 Mar 2019	Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% 5 mL bottles, Rx only, Allergan, Inc. Irvine, CA 92612 U.S.A. NDC 0023-9211-05	Drug	Class II	1	Terminated
19 Oct 2017	Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, Rx only, packaged in a) 2.5 mL NDC# 0023-9211-03; b) 5 mL (NDC# 0023-9211-05); c) 10 mL (NDC# 0023-9211-10); d) 15 mL (NDC# 0023-9211-15) bottles, Manufactured By: Allergan, Irvine, CA 92612..	Drug	Class III	2	Terminated
1 May 2017	Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile, 3.5 g tube, RX only, Manufactured by Allergan, Irvine, California, 92612, U.S.A., NDC: 0023-0313-04.	Drug	Class II	1	Terminated
16 Mar 2017	Lumigan (bimatoprost ophthalmic solution) 0.01%, 7.5 mL bottle, Rx only, Allergan Irvine, CA 92612, NDC 0023-3205-08.	Drug	Class III	1	Terminated
30 Jun 2016	TAZORAC (tazarotene) Gel 0.05%, Rx only, For Dermatologic Use Only, Not for Ophthalmic Use, packaged in a) 30 g tubes (NDC: 0023-8335-03, UPC: 300238335036) and b)100 g tubes,(NDC: 0023-8335-10, UPC: 300238335104), Manufactured by: Allergan Inc., Irvine, CA 92512.	Drug	Class II	2	Terminated
10 May 2016	Tazorac (tazarotene) Gel 0.05%, Rx only, packaged in a) 30g (NDC 0023-8335-03) and b) 100g (NDC 0023-8335-10) tubes, Allergan Inc, Irvine, CA 92612	Drug	Class II	2	Terminated
24 Aug 2015	Refresh Lacri-Lube (Mineral Oil 42.5% and White Petrolatum 56.8%) Lubricant Eye Ointment, packaged in a) Net wt. 0.12 oz (3.5 g) tubes (NDC 0023-0312-04) UPC 3 0023-0312-04 2 and b) Net wt. 0.25 oz (7 g) tubes (NDC 0023-0312-07) UPC 3 0023-0312-07 3, Allergan, Inc., 2525 Dupont Drive, Irvine, CA 92612.	Drug	Class II	4	Terminated

By type and class

Drug7

Device1

Class II6

Class III2

Class I: 0% of this firm's events; 18% of all events on the register.

Events by year

Enforcement events for Allergan Sales, LLC by year initiated.

Questions and answers

How many FDA recalls has Allergan Sales, LLC had?

8 enforcement events (14 product records) on this register, 2015–2024: 7 drug, 1 device.

Are any Allergan Sales, LLC recalls ongoing?

1 event is listed as ongoing in the current openFDA export.

What class are Allergan Sales, LLC recalls?

6 Class II, 2 Class III. 0% are Class I against 18% of all events on the register. Class reflects the relative degree of health hazard of the product, not the firm.

Where does this data come from?

openFDA food, drug and device enforcement reports (CC0), export dated 28 Sep 2026.

Provenance

Source: openFDA enforcement reports (CC0), export dated 28 Sep 2026. Firm names are grouped exactly as FDA spells them; the same company can appear under several spellings. Only organisations are shown. See the methodology.